First human trial begins for Long-Awaited EBV vaccine
NCT ID NCT07478952
Summary
This early-stage study is testing a new mRNA vaccine designed to prevent Epstein-Barr virus (EBV) infection. Researchers will enroll 120 healthy adults aged 18-30 to check if the vaccine is safe and triggers an immune response. The trial will compare two different injection methods—into the skin and into the muscle—to see which works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN BARR VIRUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Doherty Clinical Trials
NOT_YET_RECRUITINGMelbourne, Victoria, VIC 3149, Australia
-
Nucleus Network
RECRUITINGMelbourne, Victoria, VIC 3004, Australia
Conditions
Explore the condition pages connected to this study.